Supplemental Figures




Figure S1. Anti-SARS-CoV-2 spike antibody (IgG) signal as a function of time for recovered individuals.




Figure S2. Anti-SARS-CoV-2 spike antibody (IgG) signal for individuals >20 days after first dose of Pfizer or Moderna as a function of individual age (left) and race (right). Participants identifying as Asian had a significantly higher antibody signal than White and combined other groups. Regression of signal with age gives a significant downward trend with slope = -0.09 and P < 0.001.




Figure S3. Anti-SARS-CoV-2 spike antibody (IgG) signal for recovered individuals as a function of age. ANOVA gives P = 0.049 for differences but there is no clear trend for differences.




Figure S4. Numbers of participants giving samples as a function of reported age (top) and the distribution of individuals giving different numbers of samples (bottom).